Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Givinostat HCl
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Italfarmaco S.p.A
Deal Size : Undisclosed
Deal Type : Agreement
Italfarmaco, Medis Sign Exclusive Deal for Givinostat in 17 European Nations
Details : Under the agreement, Medis will have exclusive distribution rights of Duvyzat (Givinostat HCl). It is being indicated for the treatment of DMD.
Product Name : Duvyzat
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 18, 2025
Lead Product(s) : Givinostat HCl
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Italfarmaco S.p.A
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Mexiletine
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®
Details : Under the agreement announced today, Medis will initially focus on the commercialization of NaMuscla® in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase.
Product Name : NaMuscla
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 09, 2022
Lead Product(s) : Mexiletine
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : DS-8500a
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin
Details : DS-8500a is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2016
Lead Product(s) : DS-8500a
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Endometrial Regenerative Cell
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia
Details : Endometrial Regenerative Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Peripheral Vascular Diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 20, 2012
Lead Product(s) : Endometrial Regenerative Cell
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
